David Feltquate

David Feltquate is an accomplished drug developer in the immuno-oncology field. Prior to joining Palleon, David was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Prior to this, he held numerous leadership positions at Bristol Myers Squibb including Head of Oncology Early Clinical Development and Development Leader for Ipilimumab/Nivolumab Life Cycle Management. As the Nivolumab Clinical Head, David was responsible for the development of the first PD1 inhibitor from proof of concept through initial registrations in non-small cell lung cancer, melanoma, and renal cell carcinoma. David earned a B.S. in biology from the Massachusetts Institute of Technology and an M.D./Ph.D. in immunology from the University of Massachusetts Medical School. He completed internal medicine training at Dartmouth Hitchcock Medical Center and medical oncology training at Memorial Sloan Kettering Cancer Center.